Pembrolizumab - CISMeF

Preferred Label : Pembrolizumab;

NCIt synonyms : Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S P))gamma 4 Heavy Chain (134-218')-disulfide with Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide; Lambrolizumab; Pembrolizumab Biosimilar BCD-201; Pembrolizumab Biosimilar GME751; Pembrolizumab Biosimilar QL2107;

NCIt definition : A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.;

UNII : DPT0O3T46P;

CAS number : 1374853-91-4;

Drug name : Keytruda;

Molecule name : SCH 900475; MK-3475; BCD-201; MK 3475; GME751; SCH-900475; QL2107; GME 751;

Codes from synonyms : 394;

Details

Origin ID

C106432;

UMLS CUI

C3658706;

Automatic exact mappings (from CISMeF team)
- lambrolizumab [MeSH concept]
Currated CISMeF NLP mapping
- Pembrolizumab [ICD-11 Extension code]
- Pembrolizumab [SMS substance]
- Pembrolizumab [Anticorps monoclonal]
- Pembrolizumab (substance) [SNOMED CT concept]
- pembrolizumab [MeSH Supplementary Concept]
- pembrolizumab [MeSH concept]
- pembrolizumab [International Nonproprietary Name]
See also inter- (CISMeF)
- Product containing pembrolizumab (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Pembrolizumab (substance) [SNOMED CT concept]
- Product containing pembrolizumab (medicinal product) [SNOMED CT concept]
- pembrolizumab [International Nonproprietary Name]
- pembrolizumab [ATC Code]
- pembrolizumab [MeSH Supplementary Concept]
- pembrolizumab [MeSH concept]
Validated automatic mappings to BTNT
- pembrolizumab [ATC Code]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- HL Authorized Value Terminology [NCIt concept]
- HL Protocol Treatment Modifications Table [NCIt concept]
- HL Total Dose Table [NCIt concept]
- HemOnc Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
- NCIt COVID-19 Agent Terminology [NCIt concept]
- NCIt COVID-19 Terminology [NCIt concept]
- Operational Ontology for Radiation Oncology Prostate Cancer Terminology [NCIt concept]
has_target
- Programmed Cell Death Protein 1 [NCIt concept]
is_component_of_chemotherapy_regimen
- AC Followed by Pembrolizumab Regimen [NCIt concept]
- Axitinib/Pembrolizumab Regimen [NCIt concept]
- Bevacizumab/Carboplatin/Paclitaxel/Pembrolizumab Regimen [NCIt concept]
- Bevacizumab/Cisplatin/Paclitaxel/Pembrolizumab Regimen [NCIt concept]
- Bevacizumab/Cyclophosphamide/Pembrolizumab Regimen [NCIt concept]
- CAPOX-Pembrolizumab Regimen [NCIt concept]
- CAPOX-Pembrolizumab-Trastuzumab Regimen [NCIt concept]
- Capecitabine/Cisplatin/Pembrolizumab Regimen [NCIt concept]
- Capecitabine/Cisplatin/Pembrolizumab/Trastuzumab Regimen [NCIt concept]
- Carboplatin/Docetaxel/Pembrolizumab Regimen [NCIt concept]
- Carboplatin/Fluorouracil/Pembrolizumab Regimen [NCIt concept]
- Carboplatin/Gemcitabine/Pembrolizumab Regimen [NCIt concept]
- Carboplatin/Nab-Paclitaxel/Pembrolizumab Followed by Pembrolizumab Regimen [NCIt concept]
- Carboplatin/Nab-Paclitaxel/Pembrolizumab Regimen [NCIt concept]
- Carboplatin/Paclitaxel/Pembrolizumab Followed by Pembrolizumab Regimen [NCIt concept]
- Carboplatin/Paclitaxel/Pembrolizumab Regimen [NCIt concept]
- Carboplatin/Pembrolizumab/Pemetrexed Regimen [NCIt concept]
- Cetuximab/Pembrolizumab Regimen [NCIt concept]
- Cisplatin/Docetaxel/Pembrolizumab Regimen [NCIt concept]
- Cisplatin/Fluorouracil/Pembrolizumab Regimen [NCIt concept]
- Cisplatin/Fluorouracil/Pembrolizumab/Trastuzumab Regimen [NCIt concept]
- Cisplatin/Gemcitabine/Pembrolizumab Regimen [NCIt concept]
- Cisplatin/Nab-Paclitaxel/Pembrolizumab Regimen [NCIt concept]
- Cisplatin/Paclitaxel/Pembrolizumab Regimen [NCIt concept]
- Cisplatin/Pembrolizumab/Pemetrexed Regimen [NCIt concept]
- Cyclophosphamide/Epirubicin/Pembrolizumab Regimen [NCIt concept]
- Dabrafenib/Pembrolizumab/Trametinib Regimen [NCIt concept]
- Enfortumab Vedotin/Pembrolizumab Regimen [NCIt concept]
- FOLFOX-Pembrolizumab/Trastuzumab Regimen [NCIt concept]
- GVD/Pembrolizumab Regimen [NCIt concept]
- ICE/Pembrolizumab Regimen [NCIt concept]
- Lenvatinib/Pembrolizumab Regimen [NCIt concept]
- Low-dose Ipilimumab/Pembrolizumab Regimen [NCIt concept]
- Mitotane/Pembrolizumab Regimen [NCIt concept]
- Nab-Paclitaxel/Pembrolizumab Regimen [NCIt concept]
- Paclitaxel/Pembrolizumab Regimen [NCIt concept]
- Pembrolizumab Regimen [NCIt concept]
- Pembrolizumab/Pemetrexed Regimen [NCIt concept]
- mFOLFOX6-Pembrolizumab Regimen [NCIt concept]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients